导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.46% | 4034/4345 |
| 近一周 | -3.84% | 4445/4962 |
| 近一月 | -1.69% | 1146/4922 |
| 近一季 | -8.14% | 2844/4747 |
| 近半年 | -24.91% | 4299/4477 |
| 近一年 | -15.79% | 3434/4016 |
| 近两年 | 23.53% | 2344/2712 |
| 近三年 | -4.80% | 1808/2054 |
| 成立以来 | 76.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.65% 2407/4961 |
-18.83% 4820/5312 |
- - |
- - |
| 2025 | 25.10% 1738/4813 |
5.71% 744/3635 |
-2.85% 3384/4076 |
15.39% 2811/4524 |
5.57% 427/4813 |
| 2024 | 2.46% 1973/3463 |
-0.07% 1069/2808 |
-7.70% 2113/3014 |
12.19% 2396/3129 |
-0.98% 1560/3463 |
| 2023 | -5.15% 719/2656 |
2.52% 1342/2280 |
-5.30% 1421/2385 |
2.35% 237/2515 |
-4.54% 1086/2655 |
| 2022 | -19.68% 882/2207 |
-7.94% 263/1919 |
1.50% 1468/2016 |
-14.56% 1114/2113 |
0.61% 1478/2208 |
| 2021 | 40.52% 30/1822 |
15.96% 5/1255 |
9.59% 542/1330 |
19.95% 47/1466 |
-7.82% 1575/1822 |
| 2020 | - - |
- - |
8.39% 825/1067 |
5.00% 936/1164 |
7.63% 702/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证钢铁ETF联接C VS. 长安沪深300非周期A(740101) |